Search Thermo Fisher Scientific
- Order Status
- Quick Order
-
Don't have an account ? Create Account
Search Thermo Fisher Scientific
Prompt and early diagnosis of respiratory pathogens that cause severe illness is critical to help inform patient management, treatment decisions, and reducing the spread of disease. Confidence in testing results allows clinicians and patients to make informed decisions—including seeking medical care and/or avoiding contact with other people. While many testing options are available for respiratory testing, molecular techniques including PCR-based tests are designed to enable early virus detection, even in asymptomatic cases, and help deliver reliable answers.
PCR and RADT are two testing technologies used to detect COVID-19. It’s important to understand what they each do best and how their attributes fit your testing scenario. The infographic below summarizes their differences.
Respiratory tract infections (RTIs) can affect the upper and lower respiratory tract(1). According to the World Health Organization (WHO), lower respiratory tract infections (RTIs) are among the leading causes of death and disability worldwide(2). Most RTIs are caused by viruses and bacteria, but diagnosis can be difficult as many respiratory infections have similar clinical presentations(3).
The Applied Biosystems TaqPath COVID-19 and COVID-19 Flu A/B, RSV solutions are designed to detect common viruses including SARS-CoV-2, the influenza virus A and B (Flu A/B), and respiratory syncytial virus (RSV). The TaqPath Respiratory Viral Select Panel expands testing for viral RTIs by detecting adenovirus, parainfluenza virus 1-4 (undifferentiated), human metapneumovirus and rhinovirus /enterovirus (undifferentiated) in a single multiplex test.
The TaqPath Menu | GeneProof RTI testing portfolio offers a great solution for identifying additional important pathogens that can be difficult to detect. The portfolio covers viruses that can lead to serious illnesses (Enterovirus, Adenovirus), commonest pathogens that cause atypical pneumonia (Chlamydia pneumoniae, Mycoplasma pneumoniae) and highly infectious causative agents of tuberculosis or pertussis/parapertussis (Mycobacterium tuberculosis, Bordetella pertussis,and Bordetella parapertussis).
Want to use our solutions? Contact us for details on our limited time offer. |
Trusted worldwide
Built-in redundancy
Compatibility
Wide range of validated clinical materials
Single test for SARS-CoV-2, influenza A/B, and RSV
Affordable and scalable
Sensitive and specific RT-PCR detection
Results automated by Applied Biosystems Pathogen Interpretive Software
High specificity
Easy-to-use concept
Compatible with a wide range of real-time PCR devices
Contamination reduction
Wide range of validated clinical materials
High specificity
Easy-to-use concept
Contamination reduction
Simple laboratory workflow
More information with less samples
Compatible with a wide range of real-time PCR devices
High specificity
Easy-to-use concept
Contamination reduction
Simple laboratory workflow
Diagnostic of atypical pneumoniae
Compatible with a wide range of real-time PCR devices
High specificity
Easy-to-use concept
Contamination reduction
Simple laboratory workflow
Design according ENPEN requirements
Compatible with a wide range of real-time PCR devices
High specificity and sensitivity
Easy-to-use concept
Contamination reduction
Simple laboratory workflow
Compatible with a wide range of real-time PCR devices
High specificity
Easy-to-use concept
Contamination reduction
Wide range of validated clinical materials
Dual target detection
Compatible with a wide range of real-time PCR devices
Interested in the effect of mutations on sensitivity of the TaqPath COVID-19 diagnostic tests? Learn more ›
Looking for research solutions for investigating respiratory pathogens? Click below to view Research Use Only (RUO) products covering viral, bacterial, and fungal targets in targeted or syndromic panels.
For Research Use Only. Not for use in diagnostic procedures.
Watch our on-demand webinars to learn more about how our COVID-19 Diagnostics Testing Solutions address challenges, or browse our full webinar library.
Read our blog discussing how influenza is an underestimated threat, or browse through our full blog library.
References:
1. https://pubmed.ncbi.nlm.nih.gov/21413304/
2. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates
3. https://pubmed.ncbi.nlm.nih.gov/21413304/
For In Vitro Diagnostic Use. Intended use and regulatory statements of products vary. For specific intended use and regulatory statements please refer to the Instructions for Use (IFU). Product availability by country varies. For product availability in your country, check the associated product webpages.
TaqPath™ Menu | GeneProof™ assays are manufactured by GeneProof™ and distributed by Thermo Fisher Scientific
© 2023 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries. GeneProof™ is the property of GeneProof.